0001193125-18-079317.txt : 20180416 0001193125-18-079317.hdr.sgml : 20180416 20180312164056 ACCESSION NUMBER: 0001193125-18-079317 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcus Biosciences, Inc. CENTRAL INDEX KEY: 0001724521 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473898435 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 BUSINESS PHONE: 650-489-9000 MAIL ADDRESS: STREET 1: 3928 POINT EDEN WAY CITY: HAYWARD STATE: CA ZIP: 94545 CORRESP 1 filename1.htm CORRESP

March 12, 2018

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 4561

100 F Street, N.E.

Washington, D.C. 20549-3720

 

Attention:    Ada Sarmento, Staff Attorney
  

Suzanne Hayes, Assistant Director

Office of Healthcare and Insurance

 

Re: Arcus Biosciences, Inc.

Registration Statement on Form S-1 (File No. 333-223086)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Arcus Biosciences, Inc. (the “Registrant”) hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-223086) (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Time on March 14, 2018, or as soon thereafter as practicable.

The Registrant hereby acknowledges that:

(i) should the Securities and Exchange Commission (the “Commission”) or the staff (the “Staff”), acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;

(ii) the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and

(iii) the Registrant may not assert comments of the Commission or the Staff and the declaration of effectiveness of the Registration Statement as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

The Registrant hereby authorizes Heidi Mayon or Richard Blake, both of whom are attorneys with the Registrant’s outside legal counsel, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP, to orally modify or withdraw this request for acceleration.

 

1

The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Mayon at (650) 463-5381 or, in her absence, Mr. Blake at (650) 463-5432.

 

Sincerely,
Arcus Biosciences, Inc.
By:  

/s/ Terry Rosen

  Terry Rosen, Ph.D.
  Chief Executive Officer

 

2